Nanoparticles and modulation of immune responses

Science Progress

Volumn 94, Issue 1, 2011, Pages 97-107

  Pantic, Igor ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Adaptive; Dendritic; Immonotoxicity; Immune; Innate; Nanoparticle; Opsonization; Pegylation; Phagocytosis; Vaccine

Indexed keywords

NANOPARTICLE; OPSONIN;

ADAPTIVE IMMUNITY; ANIMAL; DRUG DELIVERY SYSTEM; DRUG EFFECT; HUMAN; IMMUNE SYSTEM; IMMUNOMODULATION; INNATE IMMUNITY; NANOTECHNOLOGY; PHAGOCYTOSIS; REVIEW;

ADAPTIVE IMMUNITY; ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNE SYSTEM; IMMUNITY, INNATE; IMMUNOMODULATION; NANOPARTICLES; NANOTECHNOLOGY; OPSONIN PROTEINS; PHAGOCYTOSIS;

EID: 79957984095     PISSN: 00368504     EISSN: None     Source Type: Journal    
DOI: 10.3184/003685011X12979697342151     Document Type: Article

References (44)

1. Pantic, I. (2010) Magnetic nanoparticles in cancer diagnosis and treatment: novel approaches. Rev. Adv. Mater. Sci., 26, 14-34.
2. Powell, A.C., Paciotti, G.F. and Libutti, S.K. (2010) Colloidal gold: a novel nanoparticle for targeted cancer therapeutics. Methods Mol. Biol., 624, 375-384.
3. Zolnik, B.S. and Sadrieh, N. (2009) Regulatory perspective on the importance of ADME assessment of nanoscale material containing drugs. Adv. Drug Deliv. Rev., 61, 422-427.
4. Petrelli, F., Borgonovo, K. and Barni, S. (2010) Targeted delivery for breast cancer therapy: the history of nanoparticle-albumin-bound paclitaxel. Expert Opin. Pharmacother., 11, 1413-1432.
5. Dobrovolskaia, M.A. and McNeil, S.E. (2007) Immunological properties of engineered nanomaterials. Nature Nanotechnology, 2, 469-478.
6. Stolnik, S., Illum, L. and Davis, S.S. (1995) Long circulating microparticulate drug carriers. Adv. Drug Deliv. Rev., 16, 195.
7. Shan, X., Liu, C., Yuan, Y., Xu, F., Tao, X., Sheng, Y. and Zhou, H. (2009) In vitro macrophage uptake and in vivo biodistribution of long-circulation nanoparticles with poly(ethylene-glycol)-modified PLA (BAB type) triblock copolymer. Colloids Surf. B. Biointerfaces, 72, 303-311.
8. Ryan, S.M., Mantovani, G., Wang, X., Haddleton, D.M. and Brayden, D.J.(2008) Advances in PEGylation of important biotech molecules: delivery aspects. Expert Opin. Drug Deliv., 5, 371-383.
9. Owens, D.E. 3rd and Peppas, N.A. (2006) Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int. J. Pharm., 307, 93-102.
10. Gonçalves, C., Torrado, E., Martins, T., Pereira, P., Pedrosa, J. and Gama, M. (2010) Dextrin nanoparticles: studies on the interaction with murine macrophages and blood clearance. Colloids Surf. B. Biointerfaces, 75(2), 483-489.
11. Zhang, Y., Kohler, N. and Zhang, M. (2002) Surface modification of superparamagnetic magnetite nanoparticles and their intracellular uptake. Biomaterials, 23, 1553-1561.
12. Zhang, Z., Jia, J., Lai, Y., Ma, Y., Weng, J. and Sun, L. (2010) Conjugating folic acid to gold nanoparticles through glutathione for targeting and detecting cancer cells. Bioorg. Med. Chem., 18, 5528-5534.
13. Pan, J. and Feng, S.S. (2009) Targeting and imaging cancer cells by folatedecorated, quantum dots (QDs)-loaded nanoparticles of biodegradable polymers. Biomaterials, 30, 1176-1183.
14. Zheng, Y., Cai, Z., Song, X., Chen, Q., Bi, Y., Li, Y. and Hou, S. (2009) Preparation and characterization of folate conjugated N-trimethyl chitosan nanoparticles as protein carrier targeting folate receptor: in vitro studies. J. Drug Target, 17, 294-303.
15. Santra, S., Liesenfeld, B., Dutta, D., Chatel, D., Batich, C.D., Tan, W., Moudgil, B.M. and Mericle, R.A. (2005) Folate conjugated fluorescent silica nanoparticles for labeling neoplastic cells. J. Nanosci. Nanotechnol., 5, 899-904.
16. Plotkin, S.A. (2009) Vaccines: the fourth century. Clin. Vaccine Immunol., 16, 1709-1719.
17. Singh, M. and Srivastava, I. (2003) Advances in vaccine adjuvants for infectious diseases. Curr. HIV Res., 1, 309-320.
18. Peek, L.J., Middaugh, C.R. and Berkland, C. (2008) Nanotechnology in vaccine delivery. Adv. Drug Deliv. Rev., 60, 915-928.
19. Adair, B.M. (2009) Nanoparticle vaccines against respiratory viruses. WileyInterdiscip. Rev. Nanomed. Nanobiotechnol., 1, 405-414.
20. Singh, M., Chakrapani, A. and O'Hagan, D. (2007) Nanoparticles and microparticles as vaccine-delivery systems. Expert Rev. Vaccines, 6, 797-808.
21. Podda, A., Del Giudice, G. and O'Hagan, D.T. (2006) MF59: a safe and potent adjuvant for human use. In: Schijns, V.E.J.C. and O'Hagan, D.T. (eds.), Immunopotentiators in modern vaccines, pp. 149-159. Academic Press, Burlington, MA.
22. Drane, D. and Pearse, M.J. (2006) The ISCOMATRIXTM adjuvant. In: Schijns, V.E.J.C. and O'Hagan, D.T. (eds.), Immunopotentiators in modern vaccines, pp. 191-215. Academic Press, Burlington, MA.
23. Kabanov, A.V. and Vinogradov, S.V. (2009) Nanogels as pharmaceutical carriers: finite networks of infinite capabilities. Angew. Chem. Int. Ed. Engl., 48, 5418-5429.
24. Oishi, M. and Nagasaki, Y. (2010) Stimuli-responsive smart nanogels for cancer diagnostics and therapy. Nanomedicine (Lond.), 5, 451-468.
25. Kitano, S., Kageyama, S., Nagata, Y., Miyahara, Y., Hiasa, A., Naota, H., Okumura, S., Imai, H., Shiraishi, T., Masuya, M., Nishikawa, M., Sunamoto, J., Akiyoshi, K., Kanematsu, T., Scott, A.M., Murphy, R., Hoffman, E.W., Old, L.J. and Shiku, H. (2006) HER2-specific T-cell immune responses in patients vaccinated with truncated HER2 protein complexed with nanogels of cholesteryl pullulan. Clin. Cancer Res., 12, 7397-7405.
26. Kageyama, S., Kitano, S., Hirayama, M., Nagata, Y., Imai, H., Shiraishi, T., Akiyoshi, K., Scott, A.M., Murphy, R., Hoffman, E.W., Old, L.J., Katayama, N. and Shiku, H. (2008) Humoral immune responses in patients vaccinated with 1- 146 HER2 protein complexed with cholesteryl pullulan nanogel. Cancer Sci., 99, 601-607.
27. Aoki, M., Ueda, S., Nishikawa, H., Kitano, S., Hirayama, M., Ikeda, H., Toyoda, H., Tanaka, K., Kanai, M., Takabayashi, A., Imai, H., Shiraishi, T., Sato, E., Wada, H., Nakayama, E., Takei, Y., Katayama, N., Shiku, H. and Kageyama, S. (2009) Antibody responses against NY-ESO-1 and HER2antigens in patients vaccinated with combinations of cholesteryl pullulan (CHP)-NY-ESO-1 and CHP-HER2 with OK-432. Vaccine, 27, 6854-6861.
28. awabata, R., Wada, H., Isobe, M., Saika, T., Sato, S., Uenaka, A., Miyata, H., Yasuda, T., Doki, Y., Noguchi, Y., Kumon, H., Tsuji, K., Iwatsuki, K., Shiku, H., Ritter, G., Murphy, R., Hoffman, E., Old, L.J., Monden, M. and Nakayama, E. (2007) Antibody response against NY-ESO-1 in CHP-NY-ESO-1 vaccinated patients. Int. J. Cancer, 120, 2178-2184.
29. Yoshikawa, T., Okada, N., Oda, A., Matsuo, K., Matsuo, K., Mukai, Y., Yoshioka, Y., Akagi, T., Akashi, M. and Nakagawa, S. (2008) Development of amphiphilic gamma-PGA-nanoparticle based tumor vaccine: potential of the nanoparticulate cytosolic protein delivery carrier. Biochem. Biophys. Res. Commun., 366(2), 408-413.
30. Yamaguchi, S., Tatsumi, T., Takehara, T., Sasakawa, A., Yamamoto, M., Kohga, K., Miyagi, T., Kanto, T., Hiramastu, N., Akagi, T., Akashi, M. and Hayashi, N. (2010) EphA2-derived peptide vaccine with amphiphilic poly(gamma-glutamic acid) nanoparticles elicits an anti-tumor effect against mouse liver tumor. Cancer Immunol Immunother., 59(5), 759-767.
31. Nakagawa, S. (2008) Efficacy and safety of poly (gamma-glutamic acid) based nanoparticles (gamma-PGA NPs) as vaccine carrier. Yakugaku Zasshi., 128(11), 1559-1565.
32. Broos, S., Lundberg, K., Akagi, T., Kadowaki, K., Akashi, M., Greiff, L., Borrebaeck, C.A. and Lindstedt, M. (2010) Immunomodulatory nanoparticles as adjuvants and allergen-delivery system to human dendritic cells: Implications for specific immunotherapy. Vaccine, 28(31), 5075-5085.
33. Vallhov, H., Qin, J., Johansson, S.M., Ahlborg, N., Muhammed, M.A., Scheynius, A. and Gabrielsson, S. (2006) The importance of an endotoxinfree environment during the production of nanoparticles used in medical applications. Nano Lett., 6(8), 1682-1686.
34. Jones, C.F. and Grainger, D.W. (2009) In vitro assessments of nanomaterial toxicity. Adv. Drug Deliv. Rev., 61(6), 438-456.
35. Gordon, E.M., Levy, J.P., Reed, R.A., Petchpud, W.N., Liu, L., Wendler, C.B. and Hall, F.L. (2008) Targeting metastatic cancer from the inside: a new generation of targeted gene delivery vectors enables personalized cancer vaccination in situ. Int. J. Oncol., 33, 665-675.
36. Chakravarthy, K.V., Bonoiu, A.C., Davis, W.G., Ranjan, P., Ding, H., Hu, R., Bowzard, J.B., Bergey, E.J., Katz, J.M., Knight, P.R., Sambhara, S. and Prasad, P.N. (2010) Gold nanorod delivery of an ssRNA immune activator inhibits pandemic H1N1 influenza viral replication. Proc. Natl. Acad. Sci. USA, 107, 10172-10177.
37. Nguyen, D.N., Chen, S.C., Lu, J., Goldberg, M., Kim, P., Sprague, A., Novobrantseva, T., Sherman, J., Shulga-Morskaya, S., de Fougerolles, A., Chen, J., Langer, R. and Anderson, D.G. (2009) Drug delivery-mediated control of RNA immunostimulation. Mol. Ther., 17, 1555-1562.
38. Subramanya, S., Kim, S.S., Abraham, S., Yao, J., Kumar, M., Kumar, P., Haridas, V., Lee, S.K., Shultz, L.D., Greiner, D.N.M. and Shankar, P. (2010) Targeted delivery of small interfering RNA to human dendritic cells to suppress dengue virus infection and associated proinflammatory cytokine production. J. Virol., 84, 2490-2501.
39. Dobrovolskaia, M.A., Germolec, D.R. and Weaver, J.L. (2009) Evaluation of nanoparticle immunotoxicity. Nature Nanotechnol., 4, 411-414.
40. Ladics, G.S. (2007) Primary immune response to sheep red blood cells (SRBC) as the conventional T-cell dependent antibody response (TDAR) test. J. Immunotoxicol., 4, 149-52.
41. Turjacanin, D., Pantic, I. and Ristic, S. (2009) Effects of prolonged administration of lysine-acetylsalicylate on humoral immune response in guinea-pigs. Second congress of physiological sciences of Serbia with international participation, p. 147. Kragujevac, Serbia, Abstract Book.
42. Kedmi, R., Ben-Arie, N. and Peer, D. (2010) The systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activation. Biomaterials, 31, 6867-6875.
43. Schanen, B.C., Karakoti, A.S., Seal, S., Drake, D.R. 3rd, Warren, W.L. and Self, W.T. (2009) Exposure to titanium dioxide nanomaterials provokes inflammation of an in vitro human immune construct. ACS Nano, 3, 2523-2532.
44. Ainslie, K.M., Tao, S.L., Popat, K.C., Daniels, H., Hardev, V., Grimes, C.A. and Desai, T.A. (2009) In vitro inflammatory response of nanostructured titania, silicon oxide, and polycaprolactone. J. Biomed. Mater. Res. A, 91, 647-655.